A long-acting antiretroviral drug administered as an injection every two months has been found to offer ‘powerful’ protection in uninfected people from HIV in a large-scale study. By ELIZABETH MERABMore by this AuthorA global study on an injectable HIV pre-exposure prophylaxis (PrEP) drug has been stopped early after researchers found the drug to be highly effective. A long-acting antiretroviral drug administered as an injection every two months has been found to offer ‘powerful’ protection in uninfected people from HIV in a large-scale study. In the case of CAB the scientists have hailed the early termination of the HPTN 083 study as good news which may fundamentally change the nature of HIV PrEP, as well as HIV prevention. The HPTN 084 trials, however, are mainly focused on showing whether the cabotegravir (CAB) jab can prevent HIV infection among uninfected women.

Source: Daily Nation May 22, 2020 05:48 UTC